Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings

被引:29
作者
Alvarado-Cabrero, Isabel [1 ]
Alderete-Vazquez, Georgia [1 ]
Quintal-Ramirez, Marissa [1 ]
Patino, Marcia [2 ]
Ruiz, Erika [1 ]
机构
[1] Mexican Oncol Hosp, Natl Med Ctr, Dept Pathol, Mexico City 06720, DF, Mexico
[2] SOLCA, Inst Canc, Dept Pathol, Cuenca 10974, Ecuador
关键词
Locally advanced breast cancer; Neoadjuvant chemotherapy; Pathologic response; SURGICAL ADJUVANT BREAST; NEOADJUVANT CHEMOTHERAPY; INDUCTION CHEMOTHERAPY; PRIMARY TUMOR; CARCINOMA; EXPRESSION; PROLIFERATION; ESTROGEN; THERAPY; NODES;
D O I
10.1016/j.anndiagpath.2009.02.003
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Neoadjuvant chemotherapy is the standard of care for patients with locally advanced breast cancer and is used increasingly for large operable breast cancer. The aim of this study was to assess the rate of pathologic complete response (pCR) in our patient population with locally advanced breast cancer and identify predictive factors for pCR after neoadjuvant chemotherapy. We studied a cohort of 205 patients and compared histologic features and biomarkers in the pretreatment biopsy with the corresponding pathologic response in the subsequent resection specimen. A pCR was defined as the absence of any microscopic evidence of tumor in the mastectomy specimen and axillary lymph node dissection. The tumor size was reduced in 60% of patients; 16 patients had a pCR. Histologic grade, histologic type, and hormone status did correlate with a pathologic response. None of the 29 invasive pure micropapillary carcinomas had a pCR. Pathologic complete response among Mexican patients with locally advanced breast cancer is low (8%), and the presence of invasive pure micropapillary carcinoma could be an independent predictor for pCR. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:151 / 157
页数:7
相关论文
共 30 条
[1]   How do we measure a residual size in Histopthology (the gold standard) after neoadjuvant chemotherapy? [J].
Apple, S. K. ;
Suthar, F. .
BREAST, 2006, 15 (03) :370-376
[2]   PRIMARY CHEMOTHERAPY TO AVOID MASTECTOMY IN TUMORS WITH DIAMETERS OF 3 CENTIMETERS OR MORE [J].
BONADONNA, G ;
VERONESI, U ;
BRAMBILLA, C ;
FERRARI, L ;
LUINI, A ;
GRECO, M ;
BARTOLI, C ;
DEYOLDI, GC ;
ZUCALI, R ;
RILKE, F ;
ANDREOLA, S ;
SILVESTRINI, R ;
DIFRONZO, G ;
VALAGUSSA, P .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (19) :1539-1545
[3]  
BONADONNA G, 1992, CANCER RES, V52, P2127
[4]  
BUZDAR AU, 2003, BREAST CANC RES TREA, V82
[5]   Neoadjuvant chemotherapy in breast cancer [J].
Charfare, H ;
Limongelli, S ;
Purushotham, AD .
BRITISH JOURNAL OF SURGERY, 2005, 92 (01) :14-23
[6]   INFLAMMATORY BREAST-CANCER - PILOT-STUDY OF INTENSIVE INDUCTION CHEMOTHERAPY (FEC-HD) RESULTS IN A HIGH HISTOLOGIC RESPONSE RATE [J].
CHEVALLIER, B ;
ROCHE, H ;
OLIVIER, JP ;
CHOLLET, P ;
HURTELOUP, P .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1993, 16 (03) :223-228
[7]   The biology of neoadjuvant chemotherapy for breast cancer [J].
Cleator, S ;
Parton, M ;
Dowsett, M .
ENDOCRINE-RELATED CANCER, 2002, 9 (03) :183-195
[8]   Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors [J].
Colleoni, M ;
Minchella, I ;
Mazzarol, G ;
Nolè, F ;
Peruzzotti, G ;
Rocca, A ;
Viale, G ;
Orlando, L ;
Ferretti, G ;
Curigliano, G ;
Veronesi, P ;
Intra, M ;
Goldhirsch, A .
ANNALS OF ONCOLOGY, 2000, 11 (08) :1057-1059
[9]   Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes [J].
Cristofanilli, M ;
Gonzalez-Angulo, A ;
Sneige, N ;
Kau, SW ;
Broglio, K ;
Theriault, RL ;
Valero, V ;
Buzdar, AU ;
Kuerer, H ;
Buccholz, TA ;
Hortobagyi, GN .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (01) :41-48
[10]  
FELDMAN LD, 1986, CANCER RES, V46, P2578